Common cytochrome p4503A (CYP3A4 and CYP3A5) and thiopurine S-methyl transferase (TPMT) polymorphisms in Turkish population

Turkish Journal of Medical Sciences

Volumn 36, Issue 1, 2006, Pages 11-15

  Aydin Sayitoǧlu, Müge ^a   Yildiz, Inci ^b   Hatirnaz, Özden ^a   Özbek, Uǧur ^a  

^a ISTANBUL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

Author keywords

CYP3A4; CYP3A5; Pharmacogenetics; TPMT

Indexed keywords

CATALYSTS; CYTOLOGY; DRUG INTERACTIONS; ENZYMES; GENES; HEALTH; PHARMACODYNAMICS;

CYP3A4; CYP3A5; PHARMACOGENETICS; TPMT;

POPULATION STATISTICS;

CYTOCHROME P450 3A4; CYTOCHROME P450 3A5; METHYLTRANSFERASE; THIOPURINE S METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; ARTICLE; BLOOD DONOR; FEMALE; GENE FREQUENCY; GENE SEQUENCE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; MALE; NORMAL HUMAN; POLYMERASE CHAIN REACTION; POPULATION RESEARCH; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; TURKEY (REPUBLIC);

EID: 32544457881     PISSN: 13000144     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2:9-39, 2001.
2. Liu TC, Lin SF, Chen T. et al. Polymorphism analysis of CYP3A5 in myeloid leukemia. Oncol Rep 9:327-9, 2002.
3. Ball SE, Scatina J, Kao J et al. Population distribution and effects on drug metabolism of a genetic variant in the 5′ promoter region of CYP3A4. Clin Pharmacol Ther 66:288-94, 1999.
4. Gellner K, Eiselt R, Hustert E et al. Genomic organization of the human CYP3A locus: identification of a new, inducible CYP3A gene. Pharmacogenetics 11:111-21, 2001.
5. Tateishi T, Watanabe M, Moriya H et al. No ethnic difference between Caucasian and Japanese hepatic samples in the expression frequency of CYP3A5 and CYP3A7 proteins. Biochem Pharmacol 57:935-9, 1999.
6. Eichelbaum M, Burk O: CYP3A genetics in drug metabolism. Nat Med 7:285-7, 2001.
7. Eiselt R, Domanski TL, Zibat A et al. Identification and functional characterization of eight CYP3A4 protein variants. Pharmacogenetics 11:447-58, 2001.
8. Relling MV, Dervieux T. Pharmacogenetics and cancer therapy. Nature Rev Cancer 1:99-108, 2001.
9. Lennard L, Chew TS, Lilleyman JS. Human thiopurine methyltransferase activity varies with red blood cell age. Br J Clin Pharmacol 52:539-46, 2001.
10. Wandel C, Witte JS, Hall JM et al. CYP3A activity in African American and European American men: population differences and functional effect of the CYP3A4*1B5′-promoter region polymorphism. Clin Pharmacol Ther 68:82-91, 2000
11. Hon YY, Fessing MY, Pui CH et al. Polymorphism of the thiopurine S-methyltransferase gene in African-Americans. Hum Mol Genet 8:371-6, 1999.
12. Kubota T, Chiba K. Frequencies of thiopurine S-methyltransferase mutant alleles (TPMT*2, *3A, *3B and *3C) in 151 healthy Japanese subjects and the inheritance of TPMT*3C in the family of a propositus. Br J Clin Pharmacol 51:475-7, 2001
13. Ameyaw MM, Collie-Duguid ES, Powrie RH et al.. Thiopurine methyltransferase alleles in British and Ghanaian populations. Hum Mol Genet 8:367-70, 1999.
14. Yates CR, Krynetski EY, Loennechen T et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 126:608-14, 1997.
15. Kuehl P, Zhang J, Lin Y et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 27:383-91, 2001.
16. Relling MV, Hancock ML, Rivera GK et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. J Natl Cancer Inst 91:2001-8, 1999.
17. McLeod HL, Siva C. The thiopurine S-methyltransferase gene locus - implications for clinical pharmacogenomics. Pharmacogenomics 3:89-98, 2002.
18. Rossi AM, Bianchi M, Guarnieri C et al. Genotype-phenotype correlation for thiopurine S-methyltransferase in healthy Italian subjects. Eur J Clin Pharmacol 57:51-4, 2001.
19. Boson WL, Romano-Silva MA, Correa H et al.. Thiopurine methyltransferase polymorphisms in a Brazilian population. Pharmacogenomics J 3:178-82, 2003.
20. Ganiere-Monteil C, Medard Y, Lejus C et al. Phenotype and genotype for thiopurine methyltransferase activity in the French Caucasian population: impact of age. Eur J Clin Pharmacol 60:89-96, 2004.
21. Kumagai K, Hiyama K, Ishioka S et al. Allelotype frequency of the thiopurine methyltransferase (TPMT) gene in Japanese. Pharmacogenetics 11:275-8, 2001.
22. Chang JG, Lee LS, Chen CM et al. Molecular analysis of thiopurine S-methyltransferase alleles in South-east Asian populations. Pharmacogenetics 12:191-5, 2002.
23. Hustert E, Haberl M, Burk O et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 11:773-9, 2001
24. King BP, Leathart JB, Mutch E et al. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 55:625-9, 2003.
25. Lamba JK, Lin YS, Thummel K et al. Common allelic variants of cytochrome P4503A4 and their prevalence in different populations. Pharmacogenetics 12:121-32, 2002.
26. Sata F, Sapone A, Elizondo G et al. CYP3A4 allelic variants with amino acid substitutions in exons 7 and 12: evidence for an allelic variant with altered catalytic activity. Clin Pharmacol Ther 67:48-56, 2000.